Trending NewsTrending NewsNASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $119.65 +1.64 (+1.39%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$118.37 -1.28 (-1.07%) As of 11/6/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Incyte Stock (NASDAQ:INCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Incyte alerts:Sign Up Key Stats Today's Range$115.00▼$119.8150-Day Range$108.62▼$128.8352-Week Range$89.25▼$132.60Volume1.49 million shsAverage Volume1.90 million shsMarket Capitalization$24.39 billionP/E Ratio63.64Dividend YieldN/APrice Target$132.86Consensus RatingHold Company Overview Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions. Incyte also markets medicines including Pemazyre for certain cancers and Monjuvi in the United States, in partnership with MorphoSys, for a type of lymphoma. Incyte continues to develop medicines across its therapeutic areas through internal research and collaborations. Hervé Hoppenot serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Incyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreINCY MarketRank™: 3.28003810042 of 5 starsIncyte scored higher than 66% of companies evaluated by MarketBeat, and ranked 279th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 12 buy ratings, 12 hold ratings, and 1 sell rating.Upside PotentialIncyte has a consensus price target of $132.86, representing about 11.0% upside from its current price of $119.65.Amount of Analyst CoverageIncyte has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth254.46% Earnings GrowthEarnings for Incyte are expected to grow by 254.46% in the coming year, from $2.24 to $7.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 63.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 63.64, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.49.Price to Earnings Growth RatioIncyte has a PEG Ratio of 4.36. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.90% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 5.32.Change versus previous monthShort interest in Incyte has recently increased by 0.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.59 News SentimentIncyte has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Incyte this week, compared to 8 articles on an average week.Search Interest28 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows11 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,726,519.00 in company stock.Percentage Held by Insiders16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCY Stock News HeadlinesLeerink Partners Reaffirms Their Buy Rating on Incyte (INCY)November 6 at 1:26 PM | theglobeandmail.com2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research InstituteNovember 6 at 10:40 AM | businesswire.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 8 at 1:00 AM | Weiss Ratings (Ad)Incyte (NASDAQ:INCY) Insider Sells $72,565.60 in StockNovember 6 at 7:07 AM | insidertrades.comBernstein Adjusts Price Target on Incyte to $108 From $104November 6 at 6:48 AM | marketscreener.comMIncyte (NASDAQ:INCY) Given New $150.00 Price Target at Leerink PartnersNovember 6 at 4:23 AM | americanbankingnews.comIncyte Corp. stock underperforms Thursday when compared to competitorsNovember 5 at 8:46 PM | marketwatch.comIncyte’s Upcoming ASH 2026 Data for ’989 Support Buy Rating; $152 Price Target UnchangedNovember 5 at 5:51 PM | tipranks.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $98.77 on January 1st, 2026. Since then, INCY stock has increased by 21.1% and is now trading at $119.65. How were Incyte's earnings last quarter? Incyte Corporation (NASDAQ:INCY) announced its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.93) by $0.33. The company's revenue was up 14.0% on a year-over-year basis. Read the conference call transcript. Who are Incyte's major shareholders? Top institutional shareholders of Incyte include Robeco Institutional Asset Management B.V. (1.09%), Pictet Asset Management Holding SA (0.48%), VIRGINIA RETIREMENT SYSTEMS ET Al (0.42%) and Allspring Global Investments Holdings LLC (0.38%). Insiders that own company stock include Pablo J Cagnoni, Mohamed Khairie Issa, Steven H Stein, Patrick A Mayes, Barry P Flannelly, Jonathan Elliott Dickinson, Vijay K Iyengar, Lee Heeson, Michael James Morrissey, Sheila A Denton and Thomas Tray. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Alibaba Group (BABA) and Tesla (TSLA). Company Calendar Last Earnings10/29/2026Today11/08/20268th Annual Wolfe Research Healthcare Conference11/10/2026Jefferies Global Healthcare Conference11/17/2026UBS Global Biopharma Conference 202611/17/2026Investor update12/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, INCY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,844Year Founded1991Price Target and Rating Average Price Target for Incyte$132.86 High Price Target$157.00 Low Price Target$90.00 Potential Upside/Downside+11.0%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)$1.88 Trailing P/E Ratio63.64 Forward P/E Ratio15.07 P/E Growth4.36Net Income$1.29 billion Net Margins6.71% Pretax Margin13.25% Return on Equity7.92% Return on Assets6.12% Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick Ratio3.75 Sales & Book Value Annual Sales$5.14 billion Price / Sales4.74 Cash Flow$6.18 per share Price / Cash Flow19.36 Book Value$27.68 per share Price / Book4.32Miscellaneous Outstanding Shares203,830,000Free Float170,811,000Market Cap$24.39 billion OptionableOptionable Beta0.78 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:INCY) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | SponsoredA monthly income idea that does not require selling sharesA $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
